on ABIONYX (EPA:ABNX)
ABIONYX Pharma: Review of the first half of 2024
ABIONYX Pharma announced consolidated sales of €2.4 million for the first half of 2024, slightly up from €2.1 million in the previous half. This performance is based entirely on the activities of IRIS Pharma, while the biotech activity generated no revenue.
The group's cash position stands at 5.3 million euros as of June 30, 2024, including the reimbursement of the Research Tax Credit (CIR) for an amount of 770,000 euros, but before the expected reimbursement of 610,000 euros for IRIS Pharma.
ABIONYX Pharma also raised €3.4 million at the end of June to strengthen its cash position, particularly in the context of the development of its sepsis program and in the United States. These funds extend the company's financial visibility until end of 2025.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news